Smoking cessation among patients enrolled in a low-dose computed tomography screening program is associated with a three- to five-time reduction in mortality, according to research (Abstract PLEN04.07) presented at the 16th World Conference on Lung Cancer (WCLC) in Denver, Colorado. The Conference was hosted by the International Association of the Study of Lung Cancer.
Rolapitant Reduced Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Cisplatin-Based Chemotherapy
In two phase III trials reported in The Lancet Oncology, Rapoport et al found that the addition of rolapitant to serotonin (5-HT3) receptor antagonist and dexamethasone treatment significantly improved complete response rates in prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic cisplatin-based chemotherapy.
Vienna, Austria - 25 Sep - 29 Sep 2015
The European Cancer Congress (ECC 2015) is a biennial congress which combines the efforts of the most important European oncology professionals with the aim of improving the prevention, diagnosis, treatment and care of cancer patients.
At our extra ordinary AGM in 2014 a change in the Constitution of SASMO now has 2 stratifications for members either a Full Member with full voting rights (people qualifying for this need to be Registered Medical Oncologists) and Associate Members who are Allied/Interested Parties who will not have voting rights.
Your membership fees for SASMO have now become due. This letter serves to inform you that the Membership fees will increase to R1000-00 for a period of 4 years membership as of 2015 for Full Members with full voting rights (Registered Medical Oncologists) and for Associated members the fee will be R500-00 for a 4 year period.
ROMANA 1 and 2
ROMANA 1 and 2, two phase 3 trials, have assessed the efficacy and safety of anamorelin hydrochloride, a selective ghrelin receptor agonist, in patients with cancer anorexia-cachexia and unresectable stage III/1V non-small-cell lung cancer (NSCLC). Patients were randomly assigned (2:1) to either anamorelin or placebo.